The co-stimulatory molecule, CD154, and its receptor CD40, have gained increasing interest as important players in the different phases of SLE and have revealed themselves as promising therapeutic targets for disease treatment [3]. The gene discussed is CD40LG; the disease is systemic lupus erythematosus.